Recent Finacing
Recent Raise
NeuroVive develops mitochondrial-protective therapies for acute cardiovascular and neurological conditions, with CicloMulsion in phase III and NeuroSTAT in phase II, and operates licensed Asian R&D subsidiaries.
Focus Areas
Recent Investors
Valuation as of 02/11/2015
Total Raised
Funding round
Investor